Cancer in Vitro Diagnostics (IVD) Market Report 2026

The cancer in vitro diagnostics (ivd) market size has grown strongly in recent years. It will grow from $14.32 billion in 2025 to $15.32 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to expansion of hospital diagnostic infrastructure, growth in biomarker-based testing, adoption of PCR and immunoassay technologies, rising cancer screening programs, improved laboratory automation.

The cancer in vitro diagnostics (ivd) market size is expected to see strong growth in the next few years. It will grow to $19.85 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing demand for personalized oncology diagnostics, rising investments in genomic sequencing, expansion of point-of-care cancer testing, growing integration of cloud-based diagnostic platforms, increasing focus on precision medicine. Major trends in the forecast period include increasing adoption of molecular and genomic cancer testing, rising use of companion diagnostics, growing integration of AI-driven data analysis, expansion of liquid biopsy applications, enhanced focus on early cancer detection.

The rising incidence of cancer is expected to drive the growth of the cancer in vitro diagnostics (IVD) market going forward. Cancer is characterized by the uncontrolled proliferation and spread of abnormal cells in the body, which can invade surrounding tissues and form tumors. The increase in cancer cases is largely due to the aging population, as longer life expectancy and lower infectious disease mortality result in more elderly individuals who are at higher risk of developing cancer. Cancer in vitro diagnostics (IVD) supports cancer management by enabling early and accurate detection, monitoring, and disease assessment through laboratory testing of patient samples, allowing timely treatment decisions and improved patient outcomes. For instance, in January 2023, the American Cancer Society, a US-based professional organization focused on eliminating cancer, reported that 1,958,310 new cancer cases and 609,820 cancer-related deaths were projected in the United States for 2023. Therefore, the rising incidence of cancer is propelling the growth of the cancer in vitro diagnostics (IVD) market.

Major companies operating in the cancer in vitro diagnostics market are focusing on innovations in cancer screening, such as blood-based colorectal cancer (CRC) screening, to offer convenient, non-invasive, and accurate early detection. Blood-based CRC screening involves detecting cancer-associated molecular changes, such as circulating tumor DNA (ctDNA), in a patient’s blood to identify colorectal cancer in average-risk individuals. For instance, in July 2024, Guardant Health, Inc., a U.S.-based precision oncology company, received U.S. Food and Drug Administration (FDA) approval for the Guardant Shield blood test as a primary colorectal cancer screening option. The test analyzes a blood sample for specific ctDNA methylation patterns and other tumor-derived markers; key features include noninvasive collection, high analytical accuracy, and integration into clinical workflows for primary screening. Applications include early detection of colorectal cancer in average-risk adults, with benefits such as improved patient adherence, earlier malignancy detection, potential reduction in late-stage diagnoses, and eligibility for Medicare reimbursement, allowing broader access to screening.

In June 2025, QIAGEN N.V., a Netherlands-based life sciences and molecular diagnostics company, partnered with Gencurix Co., Ltd., to develop QIAcuity Digital PCR IVD assays. Through this partnership, QIAGEN and Gencurix aim to enhance precision diagnostics by combining QIAGEN’s digital PCR technology with Gencurix’s biomarker discovery and assay development expertise, accelerating innovation in molecular testing and clinical applications. Gencurix Co., Ltd. is a South Korea-based biotechnology company specializing in biomarker-based diagnostics and assay solutions for precision medicine.

Major companies operating in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., Illumina Inc., Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., Tulip Diagnostics Pvt Ltd., Guardant Health Inc., Agilent Technologies Inc., BGI Genomics.

North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer in vitro diagnostics (ivd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cancer in vitro diagnostics market by increasing costs of imported reagents, sequencing instruments, diagnostic analyzers, software platforms, and laboratory automation systems. Hospitals and laboratories in North America and Europe are most affected due to dependence on imported IVD technologies, while Asia-Pacific faces cost pressure on diagnostic exports. These tariffs are increasing testing costs and delaying technology upgrades. However, they are also promoting domestic reagent production, regional instrument manufacturing, and innovation in cost-efficient diagnostic solutions.

The cancer in vitro diagnostics (ivd) market research report is one of a series of new reports that provides cancer in vitro diagnostics (ivd) market statistics, including cancer in vitro diagnostics (ivd) industry global market size, regional shares, competitors with a cancer in vitro diagnostics (ivd) market share, detailed cancer in vitro diagnostics (ivd) market segments, market trends and opportunities, and any further data you may need to thrive in the cancer in vitro diagnostics (ivd) industry. This cancer in vitro diagnostics (ivd) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer in vitro diagnostics (IVD) refers to diagnostic tests performed outside the human body on samples such as blood, tissue, or other bodily fluids to detect, monitor, or manage cancer. These tests help in early detection, diagnosis, prognosis, and treatment selection for cancer patients by analyzing biomarkers, genetic mutations, and other indicators related to cancer.

The primary product types of cancer in vitro diagnostics (IVD) are reagents and kits, instruments, and software and services. Reagents and kits refer to ready-to-use chemicals and prepared testing materials used to detect cancer markers and analyze samples in cancer IVD tests. They leverage various technologies such as clinical chemistry, immunochemistry or immunoassays, hematology, coagulation and hemostasis, microbiology, molecular diagnostics, and others. The tests cover multiple cancer types, including breast cancer, lung cancer, prostate cancer, and colorectal cancer, and cater to several end users, such as hospitals, laboratories, academic institutions, point-of-care testing centers, patient self-testing, and others.

The cancer in vitro diagnostics (IVD) market consists of revenues earned by entities by providing services such as cancer screening, early detection testing, diagnostic analysis, and personalized treatment guidance. The market value includes the value of related goods sold by the service provider or contained within the service offering. The cancer in vitro diagnostics (IVD) market also includes sales of reagents, assay kits, diagnostic instruments, molecular diagnostic platforms, and immunoassay systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.